DEFA14A: Atai Life Sciences and Beckley Psytech Announce Strategic Merger to Create Psychedelic Therapy Leader

Atai Life Sciences and Beckley Psytech have announced an all-stock business combination, aiming to create a focused pipeline of differentiated psychedelic products for mental health conditions.

Summary

• Atai Life Sciences and Beckley Psytech are combining in an all-stock transaction, with Beckley Psytech shareholders receiving 105 million Atai shares, representing approximately 34% of the pro forma combined company.
• The deal's closing is contingent on pre-negotiated success criteria for Beckley's upcoming BPL-003 Phase IIb trial, including statistical significance on the primary endpoint and no new safety signals, and is anticipated to close in the second half of 2025.
• The combined company will feature a focused pipeline of differentiated psychedelic products, including BPL-003 and VLS-01 for treatment-resistant depression (TRD), and EMP-01 for social anxiety disorder.
• BPL-003, an intranasal dry powder formulation, is designed for short duration (60-90 minutes) and single administration per clinic visit, aiming to fit into the established SPRAVATO commercial footprint.
• Open-label Phase IIa studies for BPL-003 demonstrated rapid and durable antidepressant effects, with about half of subjects achieving responder criteria (50% MADRS score reduction) and remission, sustained over 3 months, and was well-tolerated with high patient acceptability.
• The combined entity will be led by Srinivas Rao as CEO, with Cosmo Feilding Mellen as Chief Strategy Officer and Rob Conley as Chief Research and Development Officer, leveraging decades of experience in drug development.

Sentiment

Score: 8

Explanation: The document announces a strategic merger presented as highly synergistic, creating a focused pipeline with strong IP and an experienced management team. Positive open-label data for the lead asset (BPL-003) and a clear market strategy (leveraging SPRAVATO's commercial footprint) contribute to a very optimistic outlook. The contingency on Phase IIb results is a key factor, but the confidence expressed by management is high.

Positives

• The merger creates a focused pipeline of differentiated psychedelic products, including BPL-003 and VLS-01, which have the potential to be first-in-class and best-in-class short-duration compounds.
• The combined company benefits from an incredibly experienced management team with extensive backgrounds in publicly traded drug development, psychiatry, and psychedelics.
• The pipeline is wholly-owned, representing a significant strategic shift and point of differentiation for Atai.
• The company anticipates many near-term milestones and inflection points, including key Phase IIb readouts within the next 12 months.
• A strong IP portfolio for BPL-003 extends to 2043, with multiple composition of matter and methods-of-use patents granted in key regions, and additional patents pending.
• BPL-003 demonstrated rapid, durable efficacy and good tolerability in open-label Phase IIa studies, including in patients on SSRIs, with 90% of adverse events resolving on the day of dosing and 90% of participants willing to take it again.
• The short-duration, single-administration paradigm of BPL-003 and VLS-01 aligns with the established SPRAVATO commercial footprint, simplifying adoption for clinics and patients and addressing a significant unmet need in TRD.
• SPRAVATO achieved blockbuster status with $930 million in US sales in 2024, indicating a substantial market opportunity for improved interventional psychiatry therapies.
• Psychedelics generally show more durable efficacy compared to ketamine and esketamine, suggesting a potential advantage for the combined company's pipeline.
• The combination as a single public entity is expected to fully unlock the value of both Atai and Beckley Psytech assets and improve the position for future fundraising.

Risks

• The closing of the transaction is subject to pre-negotiated success criteria around the upcoming BPL-003 Phase IIb trial, including statistical significance on the primary endpoint and no new safety signals; failure to meet these criteria could prevent the deal from closing.
• Clinical trial outcomes are inherently uncertain, and the forthcoming BPL-003 Phase IIb results are critical for the progression of the lead asset and the merger.
• Regulatory approvals, including successful end-of-Phase II meetings with the FDA, are necessary for advancing product candidates to Phase III and ultimately to market.
• The company faces competition in the psychedelic therapy space from other developers like GH Research and Compass Pathways, as well as other long-duration psychedelic compounds.
• While generally well-tolerated, BPL-003 has reported side effects such as nasal irritation, nausea, and vomiting, which, though mostly mild and transient, could impact patient experience.
• Future funding will be required for subsequent clinical development of the pipeline assets, despite the improved position of the combined entity.

Future Outlook

The combined company anticipates a busy year with multiple upcoming milestones, including the BPL-003 Phase IIb readout, R007 Phase IIb results in mid-2025, and VLS-01 and EMP-01 top-line results in Q1 2026. They aim to be first to market with a short-duration psychedelic and believe the combined entity is better positioned to raise funds for future clinical development. They also have optionality to explore different indications for their compounds based on future data.

Management Comments

• "We believe this combination is going to be very synergistic and unlock a lot of value for both patients and shareholders." Srinivas G. Rao, Co-Founder & CEO, Atai Life Sciences N.V.
• "The aim was to really take the next step of developing these compounds into approved license and accessible pharmaceutical medicines for patients with mental health conditions." Cosmo Feilding Mellen, CEO & Director, Beckley Psytech Limited.
• "This is a wholly owned pipeline, which is a major point of differentiation from Atai and days past." Srinivas G. Rao, Co-Founder & CEO, Atai Life Sciences N.V.
• "We feel very confident that this is going to happen with this agent as we move forward into studies because we're showing it here from the beginning with normal controls." Rob Conley, Chief Research and Development Officer.
• "We think that the combination, a single public entity fully unlocks the value of both the Atai and Beckley Psytech assets." Srinivas G. Rao, Co-Founder & CEO, Atai Life Sciences N.V.
• "We think we're very much on track to be first to market with a short duration psychedelic." Cosmo Feilding Mellen, CEO & Director, Beckley Psytech Limited.

Industry Context

The merger positions the combined entity as a leader in the rapidly evolving psychedelic therapy space, specifically focusing on short-duration compounds for interventional psychiatry. This approach aims to improve upon existing treatments like SPRAVATO (esketamine), which achieved blockbuster status despite frequent administration requirements. The market for treatment-resistant depression alone is significant (3 million patients in the US), suggesting ample room for multiple effective therapies. The company is differentiating itself by focusing on compounds with shorter psychedelic effects and simpler administration paradigms compared to some competitors.

Comparison to Industry Standards

• **SPRAVATO (Esketamine)**: BPL-003 and VLS-01 aim to improve upon SPRAVATO's model by offering more durable efficacy with less frequent administration, despite SPRAVATO achieving blockbuster status ($930 million in US sales in 2024) and establishing a commercial footprint for interventional psychiatry.
• **GH Research (GH001)**: BPL-003's Phase IIb trial design is differentiated from GH Research's GH001 by featuring 2 months (8 weeks) of blinded follow-up (vs. 8 days for GH001), including dose ranging (8mg vs. 12mg vs. 0.3mg pseudo placebo), and utilizing an intranasal dry powder, single administration per clinic visit, which is similar to SPRAVATO's widely used device, unlike GH001's individualized inhalation device with multiple doses per visit.
• **Compass Pathways (COMP360/Psilocybin)**: Atai retains a 7% stake in Compass Pathways, which pioneered the 'perceptual dose' for placebo control, though the FDA is now reportedly less concerned about this specific aspect.
• **LSD-based therapies**: BPL-003 and VLS-01 are designed for short-duration effects (60-90 minutes), contrasting with LSD-based therapies where psychedelic effects can last 8-12 hours, offering a more convenient treatment model.

Management Changes

Corporate Governance

Related Party Transactions

• Atai Life Sciences was an early backer and investor in Beckley Psytech for approximately 1.5 years prior to the announced merger.
• Atai Life Sciences retains an approximate 7% stake in Compass Pathways.

Stakeholder Impact

• **Shareholders**: Expected to benefit from the creation of a focused, wholly-owned pipeline, strong IP, an experienced management team, and an improved position for future capital raises, potentially unlocking significant value.
• **Patients**: The primary objective is to develop approved, licensed, and accessible pharmaceutical medicines for mental health conditions, particularly treatment-resistant depression and social anxiety disorder, offering potentially more durable and convenient therapies than existing options.
• **Employees**: The executive team will integrate members from both Atai and Beckley, suggesting a collaborative environment and continuity in key roles.
• **Regulatory Authorities**: The company maintains ongoing, positive interactions with the FDA, aiming for a clear path to Phase III and market approval for its lead assets.

Next Steps

• Anticipated closing of the transaction in the second half of 2025, subject to standard approvals and BPL-003 Phase IIb success criteria.
• Forthcoming readout of BPL-003 Phase IIb results.
• Preparation for end-of-Phase II meeting with the FDA for BPL-003, contingent on positive Phase IIb data.
• Anticipated top-line results for R007 Phase IIb in mid-2025.
• Anticipated top-line results for VLS-01 and EMP-01 in Q1 2026.
• Potential spin-out of ELE-101 into a separate company, with the combined entity retaining a stake.
• Potential future business development activities, though current focus is on existing assets.

Key Dates

Recommendation

Keywords

Atai Life Sciences, Beckley Psytech, Merger, Acquisition, Psychedelic therapy, Mental health, Treatment-resistant depression, TRD, Social anxiety disorder, BPL-003, Mubafotemine benzoate, VLS-01, DMT, EMP-01, R007, SPRAVATO, Esketamine, Clinical trials, Phase IIb, Drug development, Biotechnology, Pharmaceutical, Corporate governance, SEC filing, Psychopharmacology